CoChat

Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management

Open access
McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R., Hold, G. L. · 2018 · Alimentary Pharmacology & Therapeutics
Cited by 176

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Summary: Background: The concept of an altered collective gut microbiota rather than identification of a single culprit is possibly the most significant development in inflammatory bowel disease research. We have entered the “omics” era, which now allows us to undertake large‐scale/high‐throughput microbiota analysis which may well define how we approach diagnosis and treatment of inflammatory bowel disease (IBD) in the future, with a strong steer towards personalised therapeutics. Aim: To assess current epidemiological, experimental and clinical evidence of the current status of knowledge relating to the gut microbiome, and its role in IBD, with emphasis on reviewing the evidence relating to microbial therapeutics and future microbiome modulating therapeutics. Methods: A Medline search including items ‘intestinal microbiota/microbiome’, ‘inflammatory bowel disease’, ‘ulcerative colitis’, ‘Crohn's disease’, ‘faecal microbial transplantation’, ‘dietary manipulation’ was performed. Results: Disease remission and relapse are associated with microbial changes in both mucosal and luminal samples. In particular, a loss of species richness in Crohn's disease has been widely observed. Existing therapeutic approaches broadly fall into 3 categories, namely: accession, reduction or indirect modulation of the microbiome. In terms of microbial therapeutics, faecal microbial transplantation appears to hold the most promise; however, differences in study design/methodology mean it is currently challenging to elegantly translate results into clinical practice. Conclusions: Existing approaches to modulate the gut microbiome are relatively unrefined. Looking forward, the future of microbiome‐modulating therapeutics looks bright with several novel strategies/technologies on the horizon. Taken collectively, it is clear that ignoring the microbiome in IBD is not an option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14384

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 176

Metadata

Authors
McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R., & Hold, G. L.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-10-16
Volume
47
Issue
1
Pages
26-42
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2765875974
Cited by
176
References
46
FWCI
8.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.